Pembrolizumab plus chemotherapy benefits patients with combined
Combined Positive Score. In triple negative breast cancer and urothelial carcinoma, 22c3 is scored using combined positive score, with a cutoff of cps ≥ 10.
In triple negative breast cancer and urothelial carcinoma, 22c3 is scored using combined positive score, with a cutoff of cps ≥ 10.
In triple negative breast cancer and urothelial carcinoma, 22c3 is scored using combined positive score, with a cutoff of cps ≥ 10. In triple negative breast cancer and urothelial carcinoma, 22c3 is scored using combined positive score, with a cutoff of cps ≥ 10.
